JP2014513283A - 腫瘍細胞を検出するためのステロイド受容体アッセイ - Google Patents
腫瘍細胞を検出するためのステロイド受容体アッセイ Download PDFInfo
- Publication number
- JP2014513283A JP2014513283A JP2014502816A JP2014502816A JP2014513283A JP 2014513283 A JP2014513283 A JP 2014513283A JP 2014502816 A JP2014502816 A JP 2014502816A JP 2014502816 A JP2014502816 A JP 2014502816A JP 2014513283 A JP2014513283 A JP 2014513283A
- Authority
- JP
- Japan
- Prior art keywords
- tumor cells
- circulating tumor
- sample
- patient
- steroid receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/54—Determining the risk of relapse
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
a)患者から生物学的試料(血液及び骨髄)を採取する段階と、
b)生物学的試料を循環腫瘍細胞と特異的に反応するリガンドと接触させて他のサンプル成分が実質的に除外されたような、結合された循環腫瘍細胞を生物学的試料の他のサンプル成分から分離させる段階と、
c)段階(b)のサンプルに特異的に結合する少なくとも1種の試薬に、段階(b)のサンプルを接触させる段階と、
d)段階(c)のサンプルを、細胞内のステロイド受容体に対する結合親和力を有する薬剤と接触させる段階と、
e)サンプルを解析して、ステロイド受容体を発現する循環腫瘍細胞の存在を判別する段階と、を含む。
a)循環腫瘍細胞と特異的に反応して他のサンプル成分が実質的に除外されたような、結合された循環腫瘍細胞を生物学的試料の他のサンプル成分から分離させるリガンドと、
b)循環腫瘍細胞及び患者の他のサンプル成分の一方又は両方を特異的に結合する少なくとも1種の試薬と、
c)患者の循環腫瘍細胞においてステロイド受容体に対する結合親和力を有する薬剤と、を含む。
(1) 転移性癌の患者からの循環腫瘍細胞を特徴付ける方法であって、
a)前記患者から生物学的試料(血液及び骨髄)を採取する段階と、
b)他のサンプル成分を実質的に除外して、循環腫瘍細胞と特異的に反応し、そのような結合された循環腫瘍細胞を前記生物学的試料の他のサンプル成分から分離させるリガンドと、前記生物学的試料を接触させる段階と、
c)段階(b)の前記サンプルに特異的に結合する少なくとも1種の試薬に、段階(b)の前記サンプルを接触させる段階と、
d)段階(c)の前記サンプルを、細胞内のステロイド受容体に対する結合親和力を有する薬剤と接触させる段階と、
e)前記サンプルを解析して、ステロイド受容体を発現する循環腫瘍細胞の存在を判別する段階と、
を含む方法。
(2) 前記ステロイド受容体を発現する循環腫瘍細胞の数を特定する段階を更に含む、実施態様1に記載の方法。
(3) 循環腫瘍細胞と特異的に反応する薬剤を、前記循環腫瘍細胞内の前記ステロイド受容体のN末端領域及びC末端領域の一方又は両方に連結する、実施態様1に記載の方法。
(4) 前記試薬がDAPI、サイトケラチン及びCD45陰性(CD45 neg)からなる群より選択される、実施態様1に記載の方法。
(5) 前記リガンドが前記腫瘍細胞上の上皮細胞接着エピトープに特異的に結合する、実施態様1に記載の方法。
(7) 段階(e)の前記サンプルが、マルチパラメーターフローサイトメトリー、免疫蛍光顕微鏡法、レーザー走査サイトメトリー、明視野に基づく画像解析、スペクトル画像解析、手動細胞解析、CELLSTRACKS(登録商標)解析、及び自動細胞解析からなる群から選択される少なくとも1つの方法によって解析される、実施態様1に記載の方法。
(8) 段階(b)の前記生成物を磁場にさらす段階を更に含む、実施態様6に記載の方法。
(9) 前記磁気応答粒子がコロイド状である、実施態様6に記載の方法。
(10) 前記薬剤がID5、CF11、E115(rbモノ)、ER119.3、及びSP−1(rbモノ(rb mono))からなる群より選択される抗体である、実施態様1に記載の方法。
(12) ステロイド受容体を発現する循環腫瘍細胞の存在について、患者サンプルをスクリーニングするための試験キットであって、
a)他のサンプル成分を実質的に除外して、循環腫瘍細胞と特異的に反応して、そのような結合された循環腫瘍細胞を前記生物学的試料の他のサンプル成分から分離させるリガンドと、
b)循環腫瘍細胞及び患者の他のサンプル成分の一方又は両方に特異的に結合する少なくとも1種の試薬と、
c)前記患者の前記循環腫瘍細胞においてステロイド受容体に対する結合親和力を有する薬剤と、
を含む試験キット。
Claims (12)
- 転移性癌の患者からの循環腫瘍細胞を特徴付ける方法であって、
a)前記患者から生物学的試料(血液及び骨髄)を採取する段階と、
b)他のサンプル成分を実質的に除外して、循環腫瘍細胞と特異的に反応し、そのような結合された循環腫瘍細胞を前記生物学的試料の他のサンプル成分から分離させるリガンドと、前記生物学的試料を接触させる段階と、
c)段階(b)の前記サンプルに特異的に結合する少なくとも1種の試薬に、段階(b)の前記サンプルを接触させる段階と、
d)段階(c)の前記サンプルを、細胞内のステロイド受容体に対する結合親和力を有する薬剤と接触させる段階と、
e)前記サンプルを解析して、ステロイド受容体を発現する循環腫瘍細胞の存在を判別する段階と、
を含む方法。 - 前記ステロイド受容体を発現する循環腫瘍細胞の数を特定する段階を更に含む、請求項1に記載の方法。
- 循環腫瘍細胞と特異的に反応する薬剤を、前記循環腫瘍細胞内の前記ステロイド受容体のN末端領域及びC末端領域の一方又は両方に連結する、請求項1に記載の方法。
- 前記試薬がDAPI、サイトケラチン及びCD45陰性からなる群より選択される、請求項1に記載の方法。
- 前記リガンドが前記腫瘍細胞上の上皮細胞接着エピトープに特異的に結合する、請求項1に記載の方法。
- 前記リガンドが磁気応答粒子を含む、請求項1に記載の方法。
- 段階(e)の前記サンプルが、マルチパラメーターフローサイトメトリー、免疫蛍光顕微鏡法、レーザー走査サイトメトリー、明視野に基づく画像解析、スペクトル画像解析、手動細胞解析、CELLSTRACKS(登録商標)解析、及び自動細胞解析からなる群から選択される少なくとも1つの方法によって解析される、請求項1に記載の方法。
- 段階(b)の前記生成物を磁場にさらす段階を更に含む、請求項6に記載の方法。
- 前記磁気応答粒子がコロイド状である、請求項6に記載の方法。
- 前記薬剤がID5、CF11、E115(rbモノ)、ER119.3、及びSP−1(rbモノ)からなる群より選択される抗体である、請求項1に記載の方法。
- 前記薬剤が、H222、F10及びTE111.5D11からなる群より選択される抗体である、請求項1に記載の方法。
- ステロイド受容体を発現する循環腫瘍細胞の存在について、患者サンプルをスクリーニングするための試験キットであって、
a)他のサンプル成分を実質的に除外して、循環腫瘍細胞と特異的に反応して、そのような結合された循環腫瘍細胞を前記生物学的試料の他のサンプル成分から分離させるリガンドと、
b)循環腫瘍細胞及び患者の他のサンプル成分の一方又は両方に特異的に結合する少なくとも1種の試薬と、
c)前記患者の前記循環腫瘍細胞においてステロイド受容体に対する結合親和力を有する薬剤と、
を含む試験キット。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161470618P | 2011-04-01 | 2011-04-01 | |
US61/470,618 | 2011-04-01 | ||
US13/432,248 US20120252038A1 (en) | 2011-04-01 | 2012-03-28 | Steroid receptor assays |
US13/432,248 | 2012-03-28 | ||
PCT/US2012/031338 WO2012135560A1 (en) | 2011-04-01 | 2012-03-30 | Steroid receptor assays for detecting tumor cells |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017207034A Division JP6707505B2 (ja) | 2011-04-01 | 2017-10-26 | 腫瘍細胞を検出するためのステロイド受容体アッセイ |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2014513283A true JP2014513283A (ja) | 2014-05-29 |
Family
ID=46927724
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014502816A Pending JP2014513283A (ja) | 2011-04-01 | 2012-03-30 | 腫瘍細胞を検出するためのステロイド受容体アッセイ |
JP2017207034A Active JP6707505B2 (ja) | 2011-04-01 | 2017-10-26 | 腫瘍細胞を検出するためのステロイド受容体アッセイ |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017207034A Active JP6707505B2 (ja) | 2011-04-01 | 2017-10-26 | 腫瘍細胞を検出するためのステロイド受容体アッセイ |
Country Status (20)
Country | Link |
---|---|
US (1) | US20120252038A1 (ja) |
EP (1) | EP2694971B1 (ja) |
JP (2) | JP2014513283A (ja) |
KR (1) | KR20140019823A (ja) |
CN (1) | CN103608681A (ja) |
BR (1) | BR112013025287A2 (ja) |
CA (1) | CA2831567A1 (ja) |
CY (1) | CY1123191T1 (ja) |
DK (1) | DK2694971T3 (ja) |
ES (1) | ES2793485T3 (ja) |
HR (1) | HRP20200860T1 (ja) |
HU (1) | HUE050711T2 (ja) |
IL (1) | IL228564B (ja) |
LT (1) | LT2694971T (ja) |
MX (1) | MX360225B (ja) |
PL (1) | PL2694971T3 (ja) |
PT (1) | PT2694971T (ja) |
RS (1) | RS60678B1 (ja) |
SI (1) | SI2694971T1 (ja) |
WO (1) | WO2012135560A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10253107B2 (en) * | 2012-10-26 | 2019-04-09 | The University Of Queensland | Use of endocytosis inhibitors and antibodies for cancer therapy |
CN109975097A (zh) * | 2019-04-18 | 2019-07-05 | 山东师范大学 | 一种基于适配体的肿瘤细胞染色探针组合 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5292638A (en) * | 1990-12-07 | 1994-03-08 | The Regents Of The University Of California | Method of determining functional estrogen receptors for prognosis of cancer |
JP2006208399A (ja) * | 1998-02-12 | 2006-08-10 | Immunivest Corp | 循環ガン細胞の迅速かつ効率的な単離のための方法および試薬 |
JP2007525642A (ja) * | 2003-02-27 | 2007-09-06 | イムニベスト・コーポレイション | 循環腫瘍細胞(ctc):転移癌患者における増悪までの時間、生存および療法に対する応答の早期評価 |
WO2007121459A2 (en) * | 2006-04-18 | 2007-10-25 | Wellstat Biologics Corporation | Detection of steroid receptors on circulating carcinoma cells and treatment |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2077781A1 (en) * | 1991-09-23 | 1993-03-24 | James W. Bacus | Method and apparatus for automated assay of biological specimens |
AU3374597A (en) | 1996-06-07 | 1998-01-05 | Immunivest Corporation | Magnetic separation employing external and internal gradients |
BR0207290A (pt) * | 2001-02-16 | 2005-06-07 | Immunivest Corp | Método para analisar um paciente quanto à presença de uma malignidade, célula maligna isolada das células cultivadas, vacina de tumor, molécula associada com diátese de tumor alterada, métodos para determinar alterações em moléculas associadas com diátese de tumor como um meio para predizer a eficácia da terapia, como um meio para analisar dosagem apropriada para terapia, como um meio para monitorar eficácia da terapia, como um meio para analisar progressão de câncer, para realizar uma biópsia de corpo inteiro em um paciente, e para identificar alterações em uma célula de tumor circulante relativamente a células presentes numa massa de tumor in situ, e, kit de teste para analisar uma amostra de paciente quanto à presença de uma célula maligna não-hematopoiética |
JP2005501236A (ja) * | 2001-08-23 | 2005-01-13 | イムニベスト・コーポレイション | 分析用の細胞および生物学的検体の安定化 |
IL161357A0 (en) * | 2001-10-26 | 2004-09-27 | Immunivest Corp | Multiparameter analysis of comprehensive nucleic acids and morphological features on the same sample |
CN1871517A (zh) * | 2002-02-19 | 2006-11-29 | 免疫公司 | 快速有效分离循环癌细胞的方法和试剂 |
US7011794B2 (en) | 2002-11-25 | 2006-03-14 | Immunivest Corporation | Upon a cartridge for containing a specimen sample for optical analysis |
US20040171091A1 (en) * | 2003-02-27 | 2004-09-02 | Cell Work, Inc. | Standardized evaluation of therapeutic efficacy based on cellular biomarkers |
JP5350369B2 (ja) * | 2007-05-31 | 2013-11-27 | ダコ デンマーク アクティーゼルスカブ | 乳癌治療および予後におけるesrコピー数変化の利用方法 |
US20090061456A1 (en) * | 2007-08-30 | 2009-03-05 | Allard William J | Method for predicting progression free and overall survival at each follow-up time point during therapy of metastatic breast cancer patients using circulating tumor cells |
US8071395B2 (en) * | 2007-12-12 | 2011-12-06 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and apparatus for magnetic separation of cells |
JP2010151678A (ja) * | 2008-12-25 | 2010-07-08 | Olympus Corp | 大腸癌の診断方法および大腸癌診断用キット |
WO2011002649A1 (en) * | 2009-06-30 | 2011-01-06 | Veridex, Llc | Analysis of circulating tumor-related microparticles |
EP3306321A1 (en) * | 2010-07-07 | 2018-04-11 | The Regents of The University of Michigan | Diagnosis and treatment of breast cancer |
-
2012
- 2012-03-28 US US13/432,248 patent/US20120252038A1/en not_active Abandoned
- 2012-03-30 WO PCT/US2012/031338 patent/WO2012135560A1/en active Application Filing
- 2012-03-30 PL PL12716825T patent/PL2694971T3/pl unknown
- 2012-03-30 LT LTEP12716825.0T patent/LT2694971T/lt unknown
- 2012-03-30 CN CN201280016743.7A patent/CN103608681A/zh active Pending
- 2012-03-30 CA CA2831567A patent/CA2831567A1/en not_active Abandoned
- 2012-03-30 MX MX2013011428A patent/MX360225B/es active IP Right Grant
- 2012-03-30 BR BR112013025287A patent/BR112013025287A2/pt not_active IP Right Cessation
- 2012-03-30 RS RS20200616A patent/RS60678B1/sr unknown
- 2012-03-30 DK DK12716825.0T patent/DK2694971T3/da active
- 2012-03-30 HU HUE12716825A patent/HUE050711T2/hu unknown
- 2012-03-30 EP EP12716825.0A patent/EP2694971B1/en active Active
- 2012-03-30 ES ES12716825T patent/ES2793485T3/es active Active
- 2012-03-30 JP JP2014502816A patent/JP2014513283A/ja active Pending
- 2012-03-30 SI SI201231787T patent/SI2694971T1/sl unknown
- 2012-03-30 PT PT127168250T patent/PT2694971T/pt unknown
- 2012-03-30 KR KR1020137028837A patent/KR20140019823A/ko not_active Application Discontinuation
-
2013
- 2013-09-29 IL IL228564A patent/IL228564B/en active IP Right Grant
-
2017
- 2017-10-26 JP JP2017207034A patent/JP6707505B2/ja active Active
-
2020
- 2020-05-28 HR HRP20200860TT patent/HRP20200860T1/hr unknown
- 2020-05-29 CY CY20201100488T patent/CY1123191T1/el unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5292638A (en) * | 1990-12-07 | 1994-03-08 | The Regents Of The University Of California | Method of determining functional estrogen receptors for prognosis of cancer |
JP2006208399A (ja) * | 1998-02-12 | 2006-08-10 | Immunivest Corp | 循環ガン細胞の迅速かつ効率的な単離のための方法および試薬 |
JP2007525642A (ja) * | 2003-02-27 | 2007-09-06 | イムニベスト・コーポレイション | 循環腫瘍細胞(ctc):転移癌患者における増悪までの時間、生存および療法に対する応答の早期評価 |
WO2007121459A2 (en) * | 2006-04-18 | 2007-10-25 | Wellstat Biologics Corporation | Detection of steroid receptors on circulating carcinoma cells and treatment |
JP2009538415A (ja) * | 2006-04-18 | 2009-11-05 | ウェルスタット バイオロジックス コーポレイション | 循環癌細胞におけるステロイド受容体の検出および処置 |
Non-Patent Citations (1)
Title |
---|
PAVAO MATTHEW: "ESTROGEN RECEPTOR ANTIBODIES: SPECIFICITY AND UTILITY IN DETECTION, LOCALIZATION AND ANALYSES OF EST", STEROIDS, vol. 66, JPN6015047864, 1 January 2001 (2001-01-01), US, pages 1 - 16, XP004220761, ISSN: 0003204928, DOI: 10.1016/S0039-128X(00)00143-4 * |
Also Published As
Publication number | Publication date |
---|---|
HUE050711T2 (hu) | 2020-12-28 |
MX2013011428A (es) | 2014-06-23 |
WO2012135560A1 (en) | 2012-10-04 |
PT2694971T (pt) | 2020-06-16 |
HRP20200860T1 (hr) | 2020-09-04 |
SI2694971T1 (sl) | 2020-09-30 |
KR20140019823A (ko) | 2014-02-17 |
JP2018021934A (ja) | 2018-02-08 |
CY1123191T1 (el) | 2021-10-29 |
MX360225B (es) | 2018-10-25 |
JP6707505B2 (ja) | 2020-06-10 |
ES2793485T3 (es) | 2020-11-16 |
DK2694971T3 (da) | 2020-06-02 |
IL228564A0 (en) | 2013-12-31 |
EP2694971B1 (en) | 2020-03-04 |
RS60678B1 (sr) | 2020-09-30 |
PL2694971T3 (pl) | 2020-11-02 |
IL228564B (en) | 2018-08-30 |
CN103608681A (zh) | 2014-02-26 |
US20120252038A1 (en) | 2012-10-04 |
BR112013025287A2 (pt) | 2017-11-14 |
EP2694971A1 (en) | 2014-02-12 |
LT2694971T (lt) | 2020-08-10 |
CA2831567A1 (en) | 2012-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5479355B2 (ja) | 血液中の循環黒色腫細胞の自動計数及び特徴付け | |
JP6254951B2 (ja) | 哺乳類の対象における5t4陽性循環腫瘍細胞を検出するための方法および5t4陽性がんの診断の方法 | |
JP5889883B2 (ja) | 血液中の循環黒色腫細胞を使用して黒色腫患者の臨床成果を予測する方法。 | |
JP2014521958A (ja) | 胸腔内液若しくは漿液と関連する腫瘍細胞の特徴づけによる癌の診断方法 | |
US20080113350A1 (en) | Blood test to monitor the genetic changes of progressive cancer using immunomagnetic enrichment and fluorescence in situ hybridization (FISH) | |
US20140113310A9 (en) | Cancer detection markers | |
WO2005116264A2 (en) | A blood test to monitor the genetic changes of progressive cancer using immunomagnetic enrichment and fluorescence in situ hybridization (fish) | |
JP6707505B2 (ja) | 腫瘍細胞を検出するためのステロイド受容体アッセイ | |
CN105087778A (zh) | 一种基于稀有细胞检测her-2/cep17基因状态的方法及相关试剂盒 | |
JP4590109B2 (ja) | 細胞の単一パラメータ及び複数パラメーター表現型解析のための生成物と方法 | |
EP2391890A1 (en) | Monitoring serial changs in circulating breast cancer cells in mice | |
US20210063385A1 (en) | Composition, method and kit for pathology | |
MX2010004966A (es) | Monitoreo de cambios seriales en celulas circulantes de cancer de mama en ratones. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150219 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20151112 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151201 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160229 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160809 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170106 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170627 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171026 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20171124 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20180126 |